Abstract 129P
Background
Biliary tract cancers (BTC) are classified as gallbladder tumours (GBC) and intrahepatic (iCCA) or perihilar and distal extrahepatic cholangiocarcinomas (eCCA). BTC’s 3-year recurrence rate is up to 80%. Capecitabine (CAP) is the standard for adjuvant (adj) chemotherapy (CT). We collected a retrospective multicentre Italian series of resected BTC and analysed the impact of adj CT on survival.
Methods
Main variables were ECOG performance status (PS), pre-surgical (SUR) Ca 19.9 value, type of SUR, site, histology, invasion (T), nodal status (N), vascular invasion (V) resection margins (R), grade (G). Median follow-up (FU) was estimated with reverse Kaplan-Meier (KM) approach; median RFS (RFS) and median overall survival (OS) were estimated by KM method.
Results
We included 142 all-stages BTC resected from 2005 to 2022, adj CT was given to 69 BTC. With median FU of 89 months (mo), overall RFS and OS were 17 and 30 mo. Lower ECOG PS was associated with longer RFS and OS (p<0.001). A pre-SUR Ca19.9 ≤ 29 was associated with longer RFS in iCCA (p=0.001) and OS both in iCCA (p=0.010) and GBC (p=0.019). Lower T was associated with longer RFS (p=0.002) and OS (p<0.001) in iCCA and GBC but not in eCCA. N0 status correlated with longer RFS in iCCA (p<0.001) and OS both in iCCA and GBC (p<0.006). R0 status was associated with longer RFS in eCCA (p=0.043) and GBC (p<0.001), showing longer OS only in GBC only (p<0.001). V0 status was associated with longer RFS (p=0.017) and OS (p=0.009) in iCCA . Adj CT didn’t impact both on RFS (p=0.539) and OS (p=0.978) in the whole cohort. After stratification by site, eCCA showed an advantage given by adj CT on mRFS (p=0.047). Comparing all adj CT, CAP performed better in iCCA, with a mRFS of 19 mo. Multivariate Cox regression analysis for RFS and OS was stratified for iCCA, eCCA and GBC: ECOG PS, R and N status retained significant correlation with RFS (p<0.001, p<0.001 and p=0.034, respectively) and OS (p<0.001, p<0.001, p=0.013, respectively). Pre-SUR Ca19.9 value correlated with OS (p=0.001).
Conclusions
In our series, adj CT didn’t impact on survival except for eCCA. Evaluation of multiple prognostic variables (including T, N, R and V status and pre-SUR Ca19.9) is necessary to identify a subgroup of BTC that can benefit more from adj CT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE)
Presenter: Changhoon Yoo
Session: Poster session 17
101P - Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study
Presenter: Harpreet Wasan
Session: Poster session 17
102P - Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster session 17
103P - Individual patient data (IPD) meta-analysis of randomised trials to compare efficacy of second-line fluoropyrimidine-based chemotherapy in advanced biliary tract cancer (BTC)
Presenter: Jaewon Hyung
Session: Poster session 17
104P - Final analysis of the prospective, randomized phase II STAMP trial: Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in node-positive extrahepatic cholangiocarcinoma (CCA)
Presenter: Hyehyun Jeong
Session: Poster session 17
105P - A phase II study of SHR-1316 plus IBI310 in patients with advanced intrahepatic cholangiocarcinoma after failure of first-line therapy
Presenter: Jia Fan
Session: Poster session 17